NovoCure (NVCR) Return on Sales (2014 - 2026)

NovoCure has disclosed Return on Sales across 13 years of filings, most recently posting 0.0% for Q1 2026.

• Return on Sales for Q1 2026 came in at 0.0%, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY), and the FY2025 annual result was 0.0%, changed 0.0% from the prior year.
• Return on Sales came in at 0.0% for Q1 2026 at NovoCure, down from 0.0% in the prior quarter.
• In the past five years, Return on Sales ranged from a high of 0.0% in Q1 2022 to a low of 0.0% in Q2 2023.
• The 5-year median for Return on Sales is 0.0% (2025), against an average of 0.0%.
• Peak annual rise in Return on Sales reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
• NovoCure's Return on Sales stood at 0.0% in 2022, then fell by 21 bps to 0.0% in 2023, then decreased by 16 bps to 0.0% in 2024, then surged by 66 bps to 0.0% in 2025, then slumped by 191 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.